THE ROLE OF BETA-BLOCKERS IN DILATED CARDIOMYOPATHY

Until recently, beta-adrenergic blockers were considered contraindicated for use in patients with heart failure, even though they had been initially given to patients with dilated cardiomyopathy almost 20 years ago. This review discusses the renewed interest in using beta-adrenergic blockers in the treatment of congestive heart failure secondary to idiopathic dilated cardiomyopathy. Rationale for the use of these agents, as well as recent clinical reports on heart function, morbidity (both short- and long-term effects), and mortality are discussed. The possible mechanisms by which beta-blockers improve the status of patients with dilated cardiomyopathy are also reviewed.